The Fountain Of Youth By Novartis


Novartis AG (NVS) Researchers Claim to Have Discovered “Fountain of Youth” Drug

Tongue in cheek I have to say that I hope I live so long to see this.

December 29, 2014

By Mark Terry, BioSpace.com Breaking News Staff

Researchers with Swiss-based Novartis (NVS) have published an article with the journal Science Translational Medicine that suggests a new drug may extend life span. The article, titled “mTOR inhibition improves immune function in the elderly,” was published by Joan Mannick and other researchers affiliated with Novartis.

The study specifically looks at an experimental drug, RAD001 (rapamycin), a member of the mTOR inhibitors class of drugs. More than 200 individuals age 65 or older received either the drug or a placebo. They were then given a dose of the flu vaccine. Those who received rapamycin showed 20 percent more antibodies in response to the vaccine.

“It sets the stage for using this drug to target aging, to improve everything about aging,” said Nir Barzilai, head of the Institute for Aging Research at New York City’s Albert Einstein College of Medicine in a statement. “That’s really going to be for us a turning point in research, and we are very excited.”

Lead author Mannick is more cautious. “It’s very important to point out that the risk/benefit of MTOR inhibitors should be established in clinical trials before anybody thinks this could be used to treat aging-related conditions,” she said.

The compound interacts with a genetic signaling pathway linked with immune function and aging. So far, mTOR inhibitor drugs have been found to diminish aging and aging-related diseases and disorders in experimental animals.

In addition to increasing immune response to the influenza vaccine, RAD001 decreased the percentage of CD4 and CD8 T lymphocytes that express the programmed death-1 (PD-1) receptor. This inhibits T cell signaling, and as mammals age, is more highly expressed.

“Aging is the major risk factor for the killers we’re afraid of,” said Barzilai in a statement. “If the aging is the major risk, the way to extend people’s lives and improve their health is to delay aging.”

Novartis has reported earlier successes with related mTOR compounds. In September the company presented the final results of a Phase III trial of Afinitor (everolimus) in patients with well-differentiated advanced and progressive pancreatic neuroendocrine tumors (pNET). This was part of the RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors) trial. mTOR (mammalian target of rapamycin) inhibition was confirmed in advanced pNET. The results of the study indicated a median overall survival (OS) of 44.02 months in patients receiving everolimus, compared to 37.68 months in those receiving placebo.

Novartis has more than 25 years of helping to advance NET care and this study, part of the largest global clinical program in NET, emphasizes our commitment to helping fulfill unmet needs for patients living with this disease,” said Alessandro Riva, Global Head, Novartis Oncology Development and Medical Affairs in a statement.


Facebooktwitterredditpinterestlinkedinmailby feather

John Macey

I was born, and principally educated, in the fields of biochemistry, and business management in the northeastern USA. However, my world-wide professional career has greatly expanded upon that US base to involve the many different segments of the Biotech / Life Science fields globally. – I have been dressed as a surgeon to view many, many surgical proceedures - The major players in the health care fields that I have worked for include: Johnson & Johnson, DuPont, Abbott Laboratories, and F. Hoffmann-La Roche. – Positions have included selling nuclear materials for both in-vivo & in-vitro (radio-pharmaceutical & radio-immunoassay) medical diagnostic purposes, in the four countries in Scandinavia, based south of Stockholm, to managing Ph. Ds at a global Swiss headquarters location. – At one time I held a position of Strategy Manager for Europe, Middle-East & Africa (EME&A) for a Chicago based company, but living in Germany. – I do speak fluent colloquial German. – In addition to having lived in multiple European countries, my professional career took me to Asia for well over a decade. There I had management control of Oceania, the Pacific Rim, Northern Asia, Japan, out to India. – Occasionally, management assignments have taken me to all of Latin America, and most of South America. – I am extremely culturally aware, a skilled negotiator, and a seasoned manager of men and science. – My one abiding passion has always been computing, data, and analysis. As such, my main computer operating system is Linux, and open-source computer applications. – I do also run Microsoft 7, and Mac OS X (all 3 operating systems on the same H-P Ultrabook). I hope you enjoy your time on the Blog, and should you have any comments / feedback please feel free to email me @ jjmacey@jjmacey.net, or visit my Linux Web Site @ www.jjmacey.net (always evolving) – John J. Macey – AKA Adler, which in German means Eagle – Wildwood, New Jersey - Together, we can expand your global markets - with our partnerships. The partnerships are global utlizing multiple Law, Regulatory, Seasoned Management, Employment, M&A and buidlers of Business. Contact use.